Melane Sampson, Author at BioTuesdays

Developments

Firefly announces discovery of new brain wave biomarkers for differential diagnosis of ADHD

Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in research using resting EEG/cognitive EEG (ERP) brain scans, collected on its FDA 510(k)-cleared Evoke System, to potentially distinguish among the three...

March 13, 2026

Executive Moves

MindMaze appoints Zach Henderson as CEO

MindMaze Therapeutics (SIX: MMTX) has announced the appointment of health tech veteran Zach Henderson as chief executive officer (CEO). With more than 30 years of experience scaling healthcare technology platforms and...

March 12, 2026

Developments

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

REGENXBIO (NASDAQ: RGNX) has announced new positive interim data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202—a potential best-in-class therapy for Duchenne muscular dystrophy (DMD). Trial investigator Carolina...

March 11, 2026

Developments

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI...

March 11, 2026

Executive Moves

Dr. Torsten Malmström joins Spago as director CMC & supply

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) has announced that Torsten Malmström, PhD, has been appointed director of chemistry, manufacturing, and controls (CMC) and joins the company’s management team. Dr. Malmström...

March 11, 2026

Developments

bioAffinity initiates longitudinal study for CyPath Lung

bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...

March 11, 2026

Developments

ACCP Journal publishes PK studies of Tonix’s TONMYA in fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced that the American College of Clinical Pharmacology (ACCP) journal Clinical Pharmacology in Drug Development published results from clinical pharmacokinetic (PK) studies...

March 6, 2026

Developments

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...

March 6, 2026

Developments

INOVIO and Akeso collaborate to advance GMB therapy

INOVIO (NASDAQ: INO) and Akeso (HKEX: 9926) have announced a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO’s DNA immunotherapy candidate, in combination with cadonilimab...

March 4, 2026

Executive Moves

Alterity names Dr. Daniel O. Claassen chief medical advisor

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that Daniel O. Claassen, MD, PhD, has been appointed chief medical advisor. In addition to this role, Dr. Claassen will retain his academic appointment as...

March 4, 2026

Author - Melane Sampson

Firefly announces discovery of new brain wave biomarkers for differential diagnosis of ADHD

MindMaze appoints Zach Henderson as CEO

REGENXBIO reports positive data from Phase 1/2 trial of RGX-202 in DMD

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Dr. Torsten Malmström joins Spago as director CMC & supply

bioAffinity initiates longitudinal study for CyPath Lung

ACCP Journal publishes PK studies of Tonix’s TONMYA in fibromyalgia

Volition announces first ever automated Nu.Q Vet Cancer Test

INOVIO and Akeso collaborate to advance GMB therapy

Alterity names Dr. Daniel O. Claassen chief medical advisor

Subscribe